

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2 Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	3 Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS	4 Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS	5 Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS	6 Mar 08	Gene Names now available in BIOSIS
NEWS	7 Mar 22	TOXLIT no longer available
NEWS	8 Mar 22	TRCTHERMO no longer available
NEWS	9 Mar 28	US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS	10 Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS	11 Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS	12 Apr 08	"Ask CAS" for self-help around the clock
NEWS	13 Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	14 Apr 09	ZDB will be removed from STN
NEWS	15 Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	16 Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	17 Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	18 Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	19 Jun 03	New e-mail delivery for search results now available
NEWS	20 Jun 10	MEDLINE Reload
NEWS	21 Jun 10	PCTFULL has been reloaded
NEWS	22 Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS EXPRESS		February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

FILE 'HOME' ENTERED AT 10:47:45 ON 10 JUL 2002

=> file medline, uspatful, embase, dgene, biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 10:48:09 ON 10 JUL 2002

FILE 'USPATFULL' ENTERED AT 10:48:09 ON 10 JUL 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:48:09 ON 10 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 10:48:09 ON 10 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 10:48:09 ON 10 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

=> s angiogenesis

L1 111350 ANGIOGENESIS

=> s l1 and inhibition

L2 18138 L1 AND INHIBITION

=> s kininogen

L3 6722 KININOGEN

=> s l3 and l2

L4 57 L3 AND L2

=> s l4 and composition

L5 30 L4 AND COMPOSITION

=> s l5 and N-terminal protective group

L6 0 L5 AND N-TERMINAL PROTECTIVE GROUP

=> s protective group

L7 9211 PROTECTIVE GROUP

=> s l7 and N-terminal

L8 835 L7 AND N-TERMINAL

=> s l8 and c-terminal

L9 598 L8 AND C-TERMINAL

=> s 19 and 15

L10 0 L9 AND L5

=> d 15 ti abs ibib 1-10

L5 ANSWER 1 OF 30 USPATFULL

TI Compositions and methods for inhibiting endothelial cell proliferation and regulating **angiogenesis** using cancer markers

AB Compositions and methods for regulating angiogenic activity wherein the compositions comprise cancer markers including kallikreins such as prostate-specific antigen (PSA), serine protease homologs, or active fragments thereof are provided. Serine proteases and kallikreins

exhibit

potent antiangiogenic activity on human and other animal cells, particularly endothelial cells. More particularly, PSA, PSA homologs, and inhibitory fragments thereof may be combined with a pharmaceutically

acceptable excipient or carrier and used to inhibit **angiogenesis** and **angiogenesis**-related diseases such as cancer, arthritis, macular degeneration, and diabetic retinopathy.

ACCESSION NUMBER: 2002:160355 USPATFULL

TITLE: Compositions and methods for inhibiting endothelial cell proliferation and regulating **angiogenesis** using cancer markers

INVENTOR(S): Holaday, John W., Bethesda, MD, United States

Fortier, Anne H., Rockville, MD, United States

PATENT ASSIGNEE(S): Entremed, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6413513	B1	20020702
APPLICATION INFO.:	US 1999-413049		19991006 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-316802, filed on 21 May 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-86586P	19980522 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Eyler, Yvonne	
ASSISTANT EXAMINER:	Andres, Janet L.	
LEGAL REPRESENTATIVE:	Kilpatrick Stockton LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1,4	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	1926	

L5 ANSWER 2 OF 30 USPATFULL

TI Interventions to mimic the effects of calorie restriction

AB Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a

relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.

ACCESSION NUMBER: 2002:144075 USPATFULL
TITLE: Interventions to mimic the effects of calorie restriction
INVENTOR(S): Spindler, Stephen R., Riverside, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406853	B1	20020618
APPLICATION INFO.:	US 2000-648642		20000825 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-471225, filed on 23 Dec 1999		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Jones, W. Gary		
ASSISTANT EXAMINER:	Taylor, Janell E.		
LEGAL REPRESENTATIVE:	Townsend & Townsend & Crew LLP		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	2230		

L5 ANSWER 3 OF 30 USPATFULL

TI Cancer treatment methods using antibodies to aminophospholipids
AB Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:143940 USPATFULL
TITLE: Cancer treatment methods using antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6406693	B1	20020618
APPLICATION INFO.:	US 1999-351543		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110608P	19981202 (60)
	US 1998-92672P	19980713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bansal, Geetha P.	
LEGAL REPRESENTATIVE:	Williams, Morgan and Amerson	

NUMBER OF CLAIMS: 63
EXEMPLARY CLAIM:
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 7541
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER.4 OF 30 USPATFULL

TI Nucleic acids, proteins, and antibodies

AB The present invention relates to novel liver related polynucleotides and

the polypeptides encoded by these polynucleotides herein collectively known as "liver antigens," and the use of such liver antigens for detecting disorders of the liver, particularly the presence of cancer

of

liver and cancer metastases. More specifically, isolated liver associated nucleic acid molecules are provided encoding novel liver associated polypeptides. Novel liver polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors,

host

cells, and recombinant and synthetic methods for producing human liver associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the liver, including cancer of liver tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and

polypeptides

of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:78442 USPATFULL

TITLE: Nucleic acids, proteins, and antibodies

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES

Ruben, Steven M., Olney, MD, UNITED STATES

Barash, Steven C., Rockville, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042096	A1	20020411
APPLICATION INFO.:	US 2001-764887	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-179065P	20000131 (60)
	US 2000-180628P	20000204 (60)
	US 2000-214886P	20000628 (60)
	US 2000-217487P	20000711 (60)
	US 2000-225758P	20000814 (60)
	US 2000-220963P	20000726 (60)
	US 2000-217496P	20000711 (60)
	US 2000-225447P	20000814 (60)
	US 2000-218290P	20000714 (60)
	US 2000-225757P	20000814 (60)
	US 2000-226868P	20000822 (60)
	US 2000-216647P	20000707 (60)
	US 2000-225267P	20000814 (60)
	US 2000-216880P	20000707 (60)
	US 2000-225270P	20000814 (60)
	US 2000-251869P	20001208 (60)
	US 2000-235834P	20000927 (60)
	US 2000-234274P	20000921 (60)
	US 2000-234223P	20000921 (60)

US 2000-228924P	20000830 (60)
US 2000-224518P	20000814 (60)
US 2000-236369P	20000929 (60)
US 2000-224519P	20000814 (60)
US 2000-220964P	20000726 (60)
US 2000-241809P	20001020 (60)
US 2000-249299P	20001117 (60)
US 2000-236327P	20000929 (60)
US 2000-241785P	20001020 (60)
US 2000-244617P	20001101 (60)
US 2000-225268P	20000814 (60)
US 2000-236368P	20000929 (60)
US 2000-251856P	20001208 (60)
US 2000-251868P	20001208 (60)
US 2000-229344P	20000901 (60)
US 2000-234997P	20000925 (60)
US 2000-229343P	20000901 (60)
US 2000-229345P	20000901 (60)
US 2000-229287P	20000901 (60)
US 2000-229513P	20000905 (60)
US 2000-231413P	20000908 (60)
US 2000-229509P	20000905 (60)
US 2000-236367P	20000929 (60)
US 2000-237039P	20001002 (60)
US 2000-237038P	20001002 (60)
US 2000-236370P	20000929 (60)
US 2000-236802P	20001002 (60)
US 2000-237037P	20001002 (60)
US 2000-237040P	20001002 (60)
US 2000-240960P	20001020 (60)
US 2000-239935P	20001013 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 19583
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 30 USPATFULL

TI Methods comprising apoptosis inhibitors for the generation of
transgenic

pigs
AB Disclosed are methods for the isolation of primordial germ cells,
culturing these cells to produce primordial germ cell-derived cell
lines, methods for transforming both the primordial germ cells and the
cultured cell lines, and using these transformed cells and cell lines
to
generate transgenic animals. The efficiency at which transgenic animals
are generated by the present invention is greatly increased, thereby
allowing the use of homologous recombination in producing transgenic
non-rodent animal species.

ACCESSION NUMBER: 2002:75643 USPATFULL
TITLE: Methods comprising apoptosis inhibitors for the
generation of transgenic pigs
INVENTOR(S): Piedrahita, Jorge A., College Station, TX, United
States
Bazer, Fuller W., College Station, TX, United States
PATENT ASSIGNEE(S): Texas A&M University System, College Station, TX,
United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: S 6369294 B1 20020409
 US 2002045253 A1 20020418
 APPLICATION INFO.: US 2001-819964 20010328 (9)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-949155, filed on 10
 Oct 1997, now patented, Pat. No. US 6271436

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46094P	19970509 (60)
	US 1996-27338P	19961011 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Crouch, Deborah	
ASSISTANT EXAMINER:	Pappu, Sita	
LEGAL REPRESENTATIVE:	Bracewell & Patterson L.L.P.	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	9398	

L5 ANSWER 6 OF 30 USPATFULL

TI Inhibitors of platelet activation and recruitment
 AB The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:4297 USPATFULL
 TITLE: Inhibitors of platelet activation and recruitment
 INVENTOR(S): Maliszewski, Charles Richard, Seattle, WA, UNITED STATES
 Gayle, Richard Brownley, III, Woodinville, WA, UNITED STATES
 Price, Virginia Lee, Seattle, WA, UNITED STATES
 Gimpel, Steven Dean, Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002002277	A1	20020103
APPLICATION INFO.:	US 2001-835147	A1	20010413 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1999-US22955, filed on 13 Oct 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104585P	19981016 (60)
	US 1998-107466P	19981106 (60)
	US 1999-149010P	19990813 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	IMMUNEX CORPORATION, LAW DEPARTMENT, 51 UNIVERSITY STREET, SEATTLE, WA, 98101	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	4075	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 30 USPATFULL

TI Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids

AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:196603 USPATFULL
TITLE: Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, United States
Ran, Sophia, Dallas, TX, United States
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6312694	B1	20011106
APPLICATION INFO.:	US 1999-351457		19990712 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Bansal, Geetha P.	
LEGAL REPRESENTATIVE:	Williams, Morgan & Amerson	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1,2,3,4	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	8243	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 30 USPATFULL

TI Xrcc3 is required for assembly of Rad51-complexes in vivo

AB The present invention relates to the interaction of Rad51 and Xrcc3 to form a complex that mediates DNA repair in eukaryotic cells. A functional Rad51/Xrcc3 complex can be introduced into a cell to increase

the resistance of the cell to DNA damaging agents. The invention also provides for a clinical application of a regimen combining Rad51 and Xrcc3 to reduce the side effects of radiotherapy and chemotherapy in a patient. In addition, the invention discloses methods for identifying candidate substances that interact with the Rad51/Xrcc3 complex. In another embodiment of the invention, preventing the formation of the Rad51/Xrcc3 complex increases the susceptibility of a cell to DNA damaging agents. This strategy can be used in combination with a DNA damaging agent or factor to kill cancerous cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:194414 USPATFULL
TITLE: Xrcc3 is required for assembly of Rad51-complexes in vivo
INVENTOR(S): Weichselbaum, Ralph R., Chicago, IL, United States
Bishop, Douglas K., Chicago, IL, United States
PATENT ASSIGNEE(S): ARCH Development Corporation. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2001036929 A1 20011101
APPLICATION INFO.: US 2001-844538 A1 20010426 (9)
RELATED APPLN. INFO.: Division of Ser. No. US 1999-404053, filed on 22 Sep 1999, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101909P	19980925 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Steven L. Highlander, Esq., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701	
NUMBER OF CLAIMS:	69	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	3206	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L5 ANSWER 9 OF 30 USPATFULL

TI **Inhibition of angiogenesis** by peptide analogs of
high molecular weight **kininogen** domain 5
AB Peptide analogs of the high molecular weight **kininogen** domain
5 are potent inhibitors of **angiogenesis**. The peptides have the
formula

X.sub.1 -(HGLGHGHEQQHGKGH)-X.sub.2 (I)

wherein

X.sub.1 is from zero to 25 amino acids;

X.sub.2 is from zero to 60 amino acids.

Methods of inhibiting endothelial cell proliferation and
angiogenesis are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:147934 USPATFULL
TITLE: **Inhibition of angiogenesis** by
peptide analogs of high molecular weight
kininogen domain 5
INVENTOR(S): Colman, Robert W., Media, PA, United States
Mousa, Shaker A., New London, PA, United States
PATENT ASSIGNEE(S): Temple University - Of The Commonwealth System of
Higher Education, Philadelphia, PA, United States
(U.S.
corporation)
Du Pont Pharmaceuticals Company, Wilmington, DE,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284726	B1	20010904
APPLICATION INFO.:	US 2000-612126		20000707 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US26377, filed on 9 Nov 1999		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-107844P	19981110 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Carlson, Karen Cochran
 ASSISTANT EXAMINER: Robinson, Patricia
 LEGAL REPRESENTATIVE: Drinker Biddle & Reath LLP
 NUMBER OF CLAIMS: 25
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Figure(s); 1 Drawing Page(s)
 LINE COUNT: 801
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 30 USPATFULL
 TI Cells and methods for the generation of transgenic pigs
 AB Disclosed are methods for the isolation of primordial germ cells, culturing these cells to produce primordial germ cell-derived cell lines, methods for transforming both the primordial germ cells and the cultured cell lines, and using these transformed cells and cell lines to generate transgenic animals. The efficiency at which transgenic animals are generated by the present invention is greatly increased, thereby allowing the use of homologous recombination in producing transgenic non-rodent animal species.

ACCESSION NUMBER: 2001:126193 USPATFULL
 TITLE: Cells and methods for the generation of transgenic pigs
 INVENTOR(S): Piedrahita, Jorge A., College Station, TX, United States
 Bazer, Fuller W., College Station, TX, United States
 PATENT ASSIGNEE(S): The Texas A & M University System, College Station, TX,
 United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6271436	B1	20010807
APPLICATION INFO.:	US 1997-949155		19971010 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-27338P	19961011 (60)
	US 1997-46094P	19970509 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Martin, Jill D.
 LEGAL REPRESENTATIVE: Williams, Morgan & Amerson
 NUMBER OF CLAIMS: 69
 EXEMPLARY CLAIM: 55
 NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
 LINE COUNT: 8905

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.61	26.82